Veru (VERU) Expected to Announce Earnings on Wednesday

Veru (NASDAQ:VERU) will likely be announcing its Q4 2025 results before the market opens on Wednesday, December 17th. Analysts expect the company to announce earnings of ($0.49) per share for the quarter. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Wednesday, December 17, 2025 at 8:00 AM ET.

Veru Trading Down 5.5%

NASDAQ VERU opened at $2.42 on Monday. Veru has a 12-month low of $2.11 and a 12-month high of $14.20. The company has a market cap of $35.47 million, a P/E ratio of -1.10 and a beta of -1.01. The company has a fifty day simple moving average of $3.08 and a 200 day simple moving average of $4.17.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Veru in a research note on Wednesday, October 8th. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Veru has a consensus rating of “Hold” and a consensus target price of $25.00.

Institutional Trading of Veru

Large investors have recently added to or reduced their stakes in the stock. Northwestern Mutual Wealth Management Co. purchased a new position in shares of Veru during the 3rd quarter worth approximately $38,000. XTX Topco Ltd acquired a new position in shares of Veru during the 2nd quarter worth about $49,000. Bank of America Corp DE increased its stake in Veru by 5.5% in the second quarter. Bank of America Corp DE now owns 185,669 shares of the company’s stock valued at $108,000 after purchasing an additional 9,637 shares during the last quarter. Jacobs Levy Equity Management Inc. acquired a new stake in Veru during the 3rd quarter worth $110,000. Finally, Raymond James Financial Inc. boosted its position in shares of Veru by 48.3% in the 2nd quarter. Raymond James Financial Inc. now owns 206,405 shares of the company’s stock valued at $120,000 after purchasing an additional 67,178 shares during the period. 47.16% of the stock is currently owned by hedge funds and other institutional investors.

About Veru

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.